Eli Lilly used EASD26 to push its next-generation obesity-and-type-2-diabetes strategy forward, highlighting new clinical results for retatrutide. Across presentations tied to the TRIUMPH-2 program, Lilly reported that the triple-agonist enabled deep weight reductions and strong metabolic improvements in people with obesity and type 2 diabetes. Lilly’s disclosed data emphasized responder rates at higher doses and continued improvements in glycemic outcomes alongside weight loss, positioning retatrutide against the growing GLP-1 competitive set. The company’s EASD update also reinforced that retatrutide may achieve obesity threshold moves for large proportions of study participants. Separate EASD26 materials also pointed to Lilly’s amylin-incretin combination, eloraTZP, as the next pillar in obesity development, with the company characterizing the weight-loss magnitude in patients with obesity and diabetes. Together, the updates show Lilly pressing for both near-term clinical differentiation and longer-horizon portfolio expansion.